KOPRAN vs ORCHPHARMA: Stock Comparison
ORCHID PHARMA is the larger company by market capitalisation. KOPRAN shows a lower P/E, a higher ROE and a higher dividend yield, while ORCHID PHARMA shows faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
KOPRAN leads 7; ORCHPHARMA leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | KOPRAN | ORCHPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | KOPRAN | ORCHPHARMA |
|---|---|---|
| Live Price | ₹232.54 | ₹954.65 |
| Day Change | 0.13% | 2.14% |
| Volume | 6.61 L | 41,657 |
| 52-Week High | ₹239.6 | ₹1,133 |
| 52-Week Low | ₹107 | ₹480 |
| Distance from 52W High | -2.95% | -15.74% |
Valuation
| Metric | KOPRAN | ORCHPHARMA |
|---|---|---|
| Market Cap | ₹1,120 Cr | ₹4,841 Cr |
| P/E Ratio | 37.34x | 448.18x |
| P/B Ratio | 1.76x | 3.07x |
| EPS | ₹1.39 | ₹2.35 |
| Book Value | ₹109.82 | ₹308.43 |
| Dividend Yield | 2.76% | 0% |
Growth
| Metric | KOPRAN | ORCHPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | -3.66% | -1.5% |
| EPS Growth (TTM YoY) | -71.88% | 0% |
| Qtr Sales Growth | -59.25% | 0% |
| Qtr Profit Growth | 0.33% | 270.21% |
Profitability & Leverage
| Metric | KOPRAN | ORCHPHARMA |
|---|---|---|
| ROE | 4.85% | 1.58% |
| ROCE | 4.89% | 2.09% |
| Net Margin | 3.78% | 2.51% |
| Operating Margin | 6.58% | 4.22% |
| Debt to Equity | 0.29x | 0.28x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | KOPRAN | ORCHPHARMA |
|---|---|---|
| Promoter Holding | 44.42% | 69.84% |
| FII Holding | 0.51%▼ 0.06 pp | 0.81%▼ 0.06 pp |
| DII Holding | 0% | 20.75%▲ 0.5 pp |
| Public Holding | 55.06%▲ 0.06 pp | 8.61%▼ 0.44 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KOPRAN and ORCHID PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.